Crashing PSTV, HUBC, BCTX & ATON Stocks

Описание: PSTV - The sharp premarket decline builds on the negative market reaction to Plus Therapeutics' January 8, 2026, Type B meeting readout with the FDA regarding REYOBIQ's pivotal trial for leptomeningeal metastases. While the discussion was constructive overall—aligning on trial design elements like randomized controls and potential accelerated approval—the FDA's rejection of circulating tumor cells (CTCs) as a validated surrogate endpoint without additional data disappointed investors expecting a faster path to approval based on prior trial results. This led to an initial 3.5% drop on January 9, followed by four consecutive days of declines through January 13, as traders reassessed development timelines and risks amid ongoing Nasdaq compliance pressures. Volume surged post-announcement, amplifying the downward momentum into today's session, with no new intervening events reported.

HUBC -- Low float, 70.34% short interest. The stock surged 56.49% during regular trading hours on January 13, 2026, driven by the previous day's announcement of Limor Zur-Stoller's appointment as Chief Financial Officer, highlighting her extensive experience in capital markets, IPOs, and M&A to support company growth. This positive development fueled buying interest, pushing the close to $0.5363. However, in after-hours trading starting at 4:00 PM ET, shares reversed sharply, dropping approximately 23-25% to around $0.40. No new negative announcements or events were reported during this period; the decline appears tied to traders securing profits after the volatile intraday rally in this low-float, small-cap security, amplified by thin after-hours liquidity. Volume data indicates heightened activity, consistent with such reversals in speculative names.

BCTX -- Low float, 15% short interest. On January 13, 2026, shares surged over 40% during regular trading hours following positive breast cancer clinical data from the company's Bria-OTS immunotherapy, closing at $10.92. However, after market close, BriaCell disclosed pricing for a $30 million public offering of units at $5.59 each—roughly half the closing price—expected to close January 15. This deeply discounted raise, involving common shares and warrants, raised immediate fears of significant shareholder dilution, prompting an initial 10% after-hours drop. The reaction intensified in premarket on January 14, with heavy selling as investors reassessed the capital influx against the lower offering terms, amplifying the decline to over 35% amid low liquidity.


ATON - AlphaTON Capital announces $15 million registered direct offering of 15 million shares at $1.00 each to fund Cocoon AI GPU scaling and general corporate purposes.

Timestamps
0:00 Intro
0:10 PSTV stock
2:09 HUBC stock
4:07 BCTX stock
6:43 ATON stock

Join this channel to get access to perks:
   / @equity4keeps  

Consider Supporting this Channel via PayPal: https://www.paypal.com/donate/?hosted...